2023
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2022
Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
Zain, Iyer S, Sica R, Ho P, Hu B, Prica A, Weng W, Kim Y, Khodadoust, Palomba M, Foss F, Tipton K, Cullingford E, Horwitz S, Sharma A, Horwitz S. Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. European Journal Of Cancer 2022, 173: s21. DOI: 10.1016/s0959-8049(22)00591-3.Peer-Reviewed Original ResearchS262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES
Iyer S, Sica R, Ho P, Hu B, Zain J, Prica A, Weng W, Kim Y, Khodadoust M, Palomba M, Foss F, Tipton K, Cullingford E, He Q, Sharma A, Horwitz S. S262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES. HemaSphere 2022, 6: 163-164. DOI: 10.1097/01.hs9.0000843940.96598.e2.Peer-Reviewed Original Research